Hello misui143, I have enjoyed reading your intelligent

New Post Public Reply Private Reply Replies (1) Message Board
blafarm misiu143 #20056
550
Hello misui143,

I have enjoyed reading your intelligent and informed posts since arriving here.

Quote:
It is very nice that you are a new poster , you are here since February 7, 2020


Yes, that is true. I recently joined after spending too much time reading caustic and baseless posts on Seeking Alpha. However, that was not my first post. If you are so inclined you can inspect my other posts using this link: https://investorshangout.com/profile/latestposts/id/62885. Feel free to also inspect my very few posts on "CYDY IH Eyes Only" board.

Quote:
But look to me that you all the way surprised !!!!!.
You surprise with any good information given by the company....not important what Dr NP or Dr Patterson said .......


Not exactly sure what you mean or what you are implying. I am thrilled with reports of what this little molecule can do. The potential indications seem to keep growing, and I find myself thinking about all of the people who can maybe be helped or saved by this drug.

I find Dr. Patterson to be extremely informed, articulate and credible. Frankly, I wish that he was the Chief Medical Officer or Chief Scientific Officer of the company, and that he participated in ALL conference calls, and ALL videos. Dr. NP has clearly accomplished what few others in the industry could ever do, through sheer will and perseverance.

Quote:
" To this day , I am particularly confused as to why BP has no interest in the company "......( how you know that ?? ))


I don't know that, this is simply what it looks like from my outside perspective. I see no investments by, no co-development with, and no licensing deals with BP. I only see a deal with V that, lets face it, is not exactly the entity one would select as a business partner, if one had other options.

Not surprisingly, this leads to confusion. Why would such an important drug not be capturing the attention of BP? More specifically, what pharmaceutical company would not want to participate, on any level, with CYDY's impressive pipeline of indications? Maybe you know more details regarding historical interest expressed by BP -- if so, please share your knowledge.

Quote:
"Discounting COVID-19 as it is completely unproven " ....( really ??, well this is not what Dr Paterson is saying )


I must admit being surprised by this remark. If I am not mistaken, I believe you might be a doctor and/or a person of science. Forgive me if I am mistaken, however, when exactly did you decide that a hypothesis was a "proven" fact -- just because someone else said it was?

In my world, hypotheses are not considered proven facts -- until they are empirically tested and confirmed to be facts. I would be absolutely thrilled if leronlimab had efficacy in treating those unfortunate souls stricken by COVID-19. There are people dying all over the world. Can you imagine if leronlimab saved those lives?

However, until such time that leronlimab is actually tested and proven to save the lives of those stricken by COVID-19 -- it remains theoretical. Yes, one can say (as Dr. Paterson has) that the MOA has a good chance of being efficacious -- but that's why every pharmaceutical company in the world conducts clinical trials. Otherwise, everyone would be taking drugs simply because someone else said it would work. Frankly, I don't know a doctor or scientist who would disagree with this logic.

Quote:
"Whatever it is , there is something wrong with this picture " ( how do you know that ?? ))


I believe that I have generally expressed this notion above. However, I guess my issue is that I don't quite understand how a molecule that has all appearances of being, literally, one of the most important drugs in the history of mankind, is not widely known, and not being aggressively courted by BP.

Let's do a quick review of potential indications:

Esophagus, Squamous Head & Neck, Melanoma, Brain-Glioblastoma, Throat, Lung including Non-Small Cell, Stomach, Colon Carcinoma, Breast, Testicular, Ovarian, Uterine, Pancreas, Bladder, Thyroid, other Endocrine, Blood/Bone Marrow CLL, AML, Hodgkin’s and non-Hodgkin’s lymphoma, other liquid/Blood Tumors, Sarcomas, Crohn’s Disease, IBS (Inflammatory Bowel Syndrome), MS (Multiple Sclerosis) , Hashimoto’s Thyroiditis, Vasculitis, Psoriasis, Polymyositis, Autoimmune Hepatitis, Graves’ Disease, Sjogren’s Syndrome, Myasthenia gravis

Have I left anything out?

So, I'm sure you can imagine how a relatively new investor, who sees this extraordinary and mind-boggling list of potential indications, and doesn't see any tangible evidence of BP interest -- might say: "there is something wrong with this picture".

Quote:
And then you say... " I am long " ...really ... why ..??


Simply put -- I want to believe. I want to believe that a single drug can miraculously address this amazing plurality of diseases. I want to believe that millions of people suffering from these diseases can maybe have the opportunity to live long, healthy, and productive lives. I want to believe that the families and friends of those inflicted will have their loved ones in their lives for many years to come. And, in the interest of full disclosure, I sure wouldn't mind a financial benefit from my support of the company relating to my investment.

I believe I have adequately addressed your questions. It does make me sad to recognize that your curious line of inquiry has the trappings of someone who thinks that I am here specifically to spread negative information for financial gain. Allow me to disabuse you of that notion. I do not short this stock. I am long and strong, that is, until such time that the investment thesis is disproved. There's nothing more I can write that will dissuade you from that incorrect characterization.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Samuel Oschin Air & Space Center Takes Flight This Fall

Updated Category News Views 110

The Grand Unveiling: November Highlights Look at this: space nerds, dreamers, and just about anybody with a heartbeat and a sense of wonder should circle November 13, 2026, like a kid with a candy store gift card. That's when the California Science Center throws open the doors to the Samuel Oschin Air and Space Center. You might as well slap a 'world's first' sticker on...

Continue Reading
BJ's Brews a New Dessert Innovation with Pizookie

Updated Category News Views 0

Banana Bread Meets Nutella in BJ's Latest Pizookie Right off the bat, let's cut to the heart of this dessert innovation. BJ's Restaurant & Brewhouse, traded under NASDAQ:BJRI, has fired up its dessert menu with something new: the Nutella® Gone Bananas Pizookie®. This isn't just another sweet treat—it’s a bold move, and if you're wondering why, you're in good...

Continue Reading
SoftwareOne Triumphs in 2026 GitHub Partner Awards

Updated Category News Views 43

SoftwareOne Nabs Prestigious GitHub Honor Outta nowhere, SoftwareOne's been lashed onto the center stage, bagging GitHub's Global Channel Sales Partner of the Year for 2026. This ain't just another shiny trophy on the shelf; it's a solid nod to their grit and strategy. Now, if good old GitHub says you're their top dog, you're obviously doing something right. Not bad for a...

Continue Reading
Newmark's Q3 2026 Financials: Revenue Surges to $3.7B

Updated Category News Views 89

Breaking Down Newmark's Latest Numbers Ah, Newmark—stepping up again with their quarterly results, and boy, it was nothing short of a spectacle. They just rolled out their third-quarter financials for 2026, and numbers don't lie; they're strutting with $3.7 billion in revenue over the past twelve months. Now, if that doesn't make the investors grin from ear to ear, I...

Continue Reading
Hehe Forum Stirs Global Harmony in Taizhou, China

Updated Category News Views 115

Reflecting on Hehe Culture's Impact Seems like everyone and their neighbor are flocking to Taizhou for the annual Hehe Culture Forum. It's not your run-of-the-mill gathering; more than 220 folks from 23 different countries showed up, diving deep into the murky waters of cultural exchange, global governance, and international cooperation. Now, if you think it's just...

Continue Reading
HiTHIUM Powers Up Australia's Energy Storage Future

Updated Category News Views 85

Just imagine, folks, a slice of the energy world reshaping right under our feet in good ol' Australia. That's the buzz HiTHIUM sparked at All Energy Australia as they showcased their fancy ?Power 6.9MWh, 8-hour long-duration battery storage system (BESS). It wasn’t just about the tech superiority but the strategic planting of stakes in the local energy market....

Continue Reading
CaringKind Merger Expands Alzheimer's Care in NY

Updated Category News Views 19

A New Chapter for Dementia Care: The CaringKind Merger Cornerstone local relationships plus a fresh westerly breeze of national presence—that's the gist of the recent union between CaringKind and Alzheimer's Disease Resource Center. This isn't just a big deal for families in Nassau and Suffolk counties, it's a seismic shift for dementia care reaching across state...

Continue Reading
Aker BP's Q3 2026: Strong Earnings Fuel Optimism

Updated Category News Views 110

Third Quarter Overview: Riding the Wave Aker BP's third quarter report is a raucous symphony of successes that have the market nodding in admiration. Marking significant strides with their offshore projects, the company seems to be in a cavalier mood as it boasts higher sales volumes and promising financials. Net production came in at 374 mboepd, dampened slightly by...

Continue Reading
Rockwell Automation Advances AI in Manufacturing Sector

Updated Category News Views 73

Rockwell Automation's Impact on AI in Manufacturing Holy smokes, Rockwell Automation, Inc. (NYSE: ROK) is cranking up the heat in the manufacturing sector with its latest foray into AI. It's 2026 and they're rolling out some innovations that could put their rivals on notice. These folks are the big cheeses in industrial automation and digital transformation, and their...

Continue Reading
WaterField Launches Shield Case for Steam Frame

Updated Category News Views 19

WaterField Shields Your VR Experience on the Move Picture this: You're deep into virtual reality gaming, and your setup is finally on point. The big but often overlooked question is—how do you lug this powerful tech around without turning it into a jumbled mess? Enter WaterField Designs with their latest creation, the Shield Case meant for Valve's Steam Frame VR...

Continue Reading

Top 5 Most Recently Viewed Articles

Evercore Insights on Potential Economic Impact of a Trump Victory

Updated Category News Views 241

Understanding Evercore's Economic Outlook Amid Political Changes As we approach a major election, Evercore ISI takes an insightful look at the dynamics of the U.S. equity market. With President Joe Biden handing over the reins to Vice President Kamala Harris as the Democratic Party's leader, the political landscape is poised for significant changes. Political Uncertainty...

Continue Reading
Innovative Beverage Lid Design Aims to Eliminate Spills

Updated Category News Views 125

Creating a Revolutionary Beverage Experience Have you ever faced the embarrassment of spills or stains while trying to enjoy your drink on the go? An innovative inventor took this common issue and transformed it into a unique solution. The invention, known as the NO DRIP LID, addresses the challenges faced by beverage lovers everywhere. Design Insight The concept behind...

Continue Reading
Highlights from Major Press Releases in September 2025

Updated Category News Views 241

Key Moments from September's Press Releases September has been a bustling month filled with noteworthy announcements from various industries. From educational rankings to exciting food offerings and groundbreaking IPOs, this month has showcased an array of significant releases that are worth revisiting. Top Headlines of September This month brought attention to a mix of...

Continue Reading
Accel Entertainment Earnings: What Investors Need to Know

Updated Category News Views 114

Accel Entertainment's Upcoming Earnings Report Accel Entertainment (NYSE: ACEL) is poised to unveil its quarterly earnings report soon, generating significant anticipation among investors. This announcement comes as the market eagerly awaits insights regarding the company's performance and outlook. Expected Financial Performance Analysts project that Accel will report an...

Continue Reading
Meet James Mitchell: New Senior VP at Midwest Institutional Trust

Updated Category News Views 498

James 'Jimmy' Mitchell Joins Midwest Institutional Trust Company Midwest Institutional Trust Company is thrilled to announce that James "Jimmy" Mitchell has been appointed as Senior Vice President. In this new role, he will primarily act as a Senior Relationship Manager for the company's Taft-Hartley Services. Additionally, he will take on the important responsibility of...

Continue Reading